{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:58:23Z","timestamp":1785484703033,"version":"3.56.0"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.lrr.2025.100557","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T06:38:53Z","timestamp":1766126333000},"page":"100557","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Long-term outcomes of pediatric AML in Tunisia: Lessons from 19 years of practice in Sousse"],"prefix":"10.1016","volume":"25","author":[{"given":"Donia","family":"Bouhoula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifa","family":"Regaieg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hela","family":"Abroug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesrine Ben","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yossra Ben","family":"Youssef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lrr.2025.100557_bib0001","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3390\/jcm11030504","article-title":"Pediatric acute myeloid leukemia\u2014past, present, and future","volume":"11","author":"Reinhardt","year":"2022","journal-title":"J. Clin. Med."},{"issue":"12","key":"10.1016\/j.lrr.2025.100557_bib0002","doi-asserted-by":"crossref","first-page":"1009\u201118","DOI":"10.1182\/blood.2021011694","article-title":"How I treat pediatric acute myeloid leukemia","volume":"138","author":"Rubnitz","year":"2021","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.lrr.2025.100557_bib0003","doi-asserted-by":"crossref","first-page":"5409\u201115","DOI":"10.1182\/blood-2011-07-364661","article-title":"Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16)","volume":"118","author":"Creutzig","year":"2011","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.lrr.2025.100557_bib0004","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1182\/blood-2015-01-623447","article-title":"A randomised comparison of daunorubicin 90mg\/m 2 vs 60mg\/m 2 in aml induction: results from the UK NCRI AML17 Trial in 1206 Patients","volume":"125","author":"Burnett","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.lrr.2025.100557_bib0005","first-page":"2873\u201183","article-title":"Management of hyperleukocytosis in pediatric acute myeloid leukemia using immediate chemotherapy without leukapheresis: results from the NOPHO-DBH AML 2012 protocol","volume":"109","author":"Zeller","year":"2024","journal-title":"Haematologica"},{"issue":"27","key":"10.1016\/j.lrr.2025.100557_bib0006","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2012.47.4874","article-title":"Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial","volume":"31","author":"Burnett","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"27","key":"10.1016\/j.lrr.2025.100557_bib0007","doi-asserted-by":"crossref","first-page":"3021\u201132","DOI":"10.1200\/JCO.2014.55.3628","article-title":"Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children\u2019s Oncology Group trial AAML0531","volume":"32","author":"Gamis","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.lrr.2025.100557_bib0008","doi-asserted-by":"crossref","first-page":"1879\u201186","DOI":"10.3324\/haematol.2019.220962","article-title":"Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children\u2019s Oncology Group","volume":"105","author":"Aplenc","year":"2020","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.lrr.2025.100557_bib0009","doi-asserted-by":"crossref","first-page":"4979\u201189","DOI":"10.1182\/blood.V87.12.4979.bloodjournal87124979","article-title":"Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children\u2019s Cancer Group","volume":"87","author":"Woods","year":"1996","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.lrr.2025.100557_bib0010","doi-asserted-by":"crossref","first-page":"9\u201116","DOI":"10.1002\/pbc.21123","article-title":"Outcomes in childhood AML in the absence of transplantation in first remission\u2013Children\u2019s Cancer Group (CCG) studies 2891 and CCG 213","volume":"50","author":"Castellino","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"issue":"27","key":"10.1016\/j.lrr.2025.100557_bib0011","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2012.47.4874","article-title":"Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial","volume":"31","author":"Burnett","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lrr.2025.100557_bib0012","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29313","article-title":"Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: a report from the Children\u2019s Oncology Group","volume":"69","author":"Getz","year":"2022","journal-title":"Pediatr. Blood Cancer"},{"issue":"4","key":"10.1016\/j.lrr.2025.100557_bib0013","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S1470-2045(20)30060-7","article-title":"Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study","volume":"21","author":"Karol","year":"2020","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.lrr.2025.100557_bib0014","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1001\/jama.2018.12512","article-title":"Effect of Levofloxacin Prophylaxis on Bacteremia in Children With Acute Leukemia or Undergoing Hematopoietic Stem Cell Transplantation: a Randomized Clinical Trial","volume":"320","author":"Alexander","year":"2018","journal-title":"JAMA"}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048925000597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048925000597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:11:34Z","timestamp":1785481894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048925000597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":14,"alternative-id":["S2213048925000597"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2025.100557","relation":{},"ISSN":["2213-0489"],"issn-type":[{"value":"2213-0489","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term outcomes of pediatric AML in Tunisia: Lessons from 19 years of practice in Sousse","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2025.100557","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100557"}}